Loading
A phase 1/2 trial of Opevesostat in prostate cancer, run by Orion Corporation, Orion Pharma, active and no longer recruiting.
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer is a phase 1/2 interventional study registered as NCT03436485 by Orion Corporation, Orion Pharma, with 204 participants enrolled, started 2018-03-19 and due to reach its primary completion in 2026-10-31. Interventions recorded: ODM-208, Midazolam. Conditions listed: Prostate Cancer Metastatic. No results are recorded here; the registry entry is the source.
Shares Opevesostat, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Opevesostat, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Opevesostat, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Opevesostat, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.